The decline of venture capital investment in early-stage life sciences poses a challenge to continued innovation

Health Affairs

Volumn 34, Issue 2, 2015, Pages 271-276

  Fleming, Jonathan J ^a  

^a Network for Excellence in Health Innovation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ARTICLE; BIOMEDICINE; BIOTECHNOLOGY; CAPITAL; DIAGNOSTIC TEST; FUNDING; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; INVESTMENT; MARKETING; MEDICAL DEVICE; PERSONALIZED MEDICINE; PRODUCT DEVELOPMENT; REIMBURSEMENT; DRUG APPROVAL; DRUG MANUFACTURE; ECONOMICS; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; LEGISLATION AND JURISPRUDENCE; PRIVATE SECTOR; PROCEDURES; STANDARDS; TRANSLATIONAL RESEARCH; TRENDS; UNITED STATES;

BIOLOGICAL SCIENCE DISCIPLINES; CAPITAL FINANCING; DRUG APPROVAL; HEALTH POLICY; HUMANS; INVESTMENTS; ORPHAN DRUG PRODUCTION; PRIVATE SECTOR; REIMBURSEMENT, INCENTIVE; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84922714689     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.1051     Document Type: Article

References (16)

1. Tufts Center for the Study of Drug Development. Cost to develop and win marketing approval for a new drug is $2.6 billion [Internet]. Boston (MA): Tufts University; 2014 Nov 18 [cited 2014 Dec 17]. Available from: http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study
2. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87(3):272-7.
3. National Venture Capital Association. Patient capital 3.0: confronting the crisis and achieving the promise of venture-backed medical innovation [Internet]. Washington (DC): NCVA; 2013 [cited 2014 Dec 17]. Available from: http://www.nvca.org/index.php?option=com_content&view=article&id=268 &Itemid=103
4. Stewart JJ, Allison PN, Johnson RS. Putting a price on biotechnology. Bioentrepreneur [serial on the Internet]. 2001 Sep [cited 2015 Jan 5]. Available from: http://www.nature.com/bioent/2003/030101/full/nbt0901-813.html
5. Svennebring AM, Wikberg JES. Net present value approaches for drug delivery. Springerplus [serial on the Internet]. 2013 Apr 1 [cited 2015 Jan 5]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622797/
6. National Venture Capital Association. Year-to-date venture capital dollars invested eclipses total dollars invested in all of 2013 [Internet]. Washington (DC): NVCA; 2014 Oct 17 [cited 2014 Dec 17]. Available from: https://www.pwcmoneytree.com/NewsFeed
7. Norris J. Trends in healthcare investments and exits 2014 [Internet]. Santa Clara (CA): Silicon Valley Bank; 2014 [cited 2014 Dec 17]. Available from: http://www.svb.com/healthcare-report/
8. Food and Drug Administration. Acceptance and filing reviews for premarket approval applications (PMAs): guidance for industry and Food and Drug Administration staff [Internet]. Silver Spring (MD): FDA; 2012 Dec 31 [cited 2014 Dec 17]. Available from: http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidance documents/ucm313368.pdf
9. Food and Drug Administration. The FDA's drug review process: ensuring drugs are safe and effective [Internet]. Silver Spring (MD): FDA; [cited 2014 Dec 17]. Available from: http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm
10. FDA Consumer Health Information. Personalized medicine and companion diagnostics go hand-in-hand [Internet]. Silver Spring (MD): Food and Drug Administration; 2014 Jul [cited 2014 Dec 17]. Available from: http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM407452.pdf
11. Food and Drug Administration. Guidance for industry. Expedited programs for serious conditions drugs and biologics [Internet]. Silver Spring (MD): FDA; 2014 May [cited 2014 Dec 17]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf
12. American Chemical Society. "Orphans" no more: renaissance in new drugs for rare diseases [Internet]. Washington (DC): ACS; 2013 May 13 [cited 2014 Dec 17]. Available from: http://www.acs.org/content/acs/en/pressroom/newsreleases/2013/may/orphans-no-more-renaissancein-new-drugs-for-rare-diseases.html
13. National Vaccine Information Center. National Childhood Vaccine Injury Act of 1986 [Internet]. Sterling (VA): NVIC; [cited 2014 Dec 17]. Available from: http://www.nvic.org/Vaccine-Laws/1986-VaccineInjury-Law.aspx
14. Rare Diseases Act of 2002, Pub. L. No. 107-280, 116 Stat. 1988-91.
15. Pew Charitable Trusts. GAIN: how a new law is stimulating the development of antibiotics [Internet]. Washington (DC): Pew Charitable Trusts; 2013 Nov 7 [cited 2014 Dec 17]. Available from: http://www.pewtrusts.org/en/researchand-analysis/issue-briefs/2013/11/07/gain-how-a-new-law-isstimulating-the-development-ofantibiotics
16. National Cancer Institute. SBIR Phase IIB Bridge Award [Internet]. Bethesda (MD): National Cancer Institute; [cited 2014 Dec 17]. Available from: http://sbir.cancer.gov/funding/phase2bridgeaward.asp#about